Etienna Bio

Etienna Bio, founded in 2021 and based in Cambridge, USA, is developing a regenerative aesthetic platform to create autologous tissue for procedures like breast augmentation and facial rejuvenation. Its core technology, licensed from the University of Massachusetts, can expand a patient's stem cells over 1,000-fold and differentiate them into adipocytes or fibroblasts. The company is led by a team with extensive regulatory and clinical experience, positioning it to address a significant market opportunity by offering a permanent, natural alternative to current synthetic solutions.

Proprietary autologous cell therapy platform for expanding a patient's stem cells from a small fat sample by >1000-fold and differentiating them into adipocytes or fibroblasts to create living, implantable tissue.

Competition includes established medical device companies (e.g., Allergan, Mentor) dominating the implant/filler market, and other biotechs working on next-generation fat grafting or allogeneic cell therapies. Etienna's key differentiator is its focus on creating fully integrated, living autologous tissue designed for permanence, a more ambitious goal than simply improving existing techniques.